Randomized Trialvery high evidence
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
The New England journal of medicine·October 3, 2024·PMID 39046157
Why it mattersThis trial demonstrates that a twice-yearly injectable PrEP option can achieve zero HIV infections in a high-incidence population of young women, addressing major adherence challenges with daily oral PrEP. It offers a highly effective, long-acting alternative that could transform HIV prevention strategies in this vulnerable group.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled